Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2021; 18(3):778-784. doi:10.7150/ijms.55361 This issue Cite

Research Paper

Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study

Sheng-Wen Wu, MD, PhD1,2, Yung-Chyuan Ho, PhD3, Ci-Wen Luo, MS4,5, Hung-Yi Chen, PhD6, Chun-Hung Su, MD, PhD7,8,9,#, Yu-Hsiang Kuan, PhD4,5,#,✉

1. Division of Nephrology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
2. The School of Medicine, Chung Shan Medical University, Taichung, Taiwan
3. School of Medical Applied Chemistry, Chung Shan Medical University, Taichung, Taiwan.
4. Department of Pharmacology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
5. Department of Pharmacy, Chung Shan Medical University Hospital, Taichung, Taiwan
6. School of Pharmacy, China Medical University, Taichung, Taiwan.
7. Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
8. Department of Internal Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
9. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
# The authors contributed equally to this work

✉ Corresponding author: Yu-Hsiang Kuan. Address: Department of Pharmacology, School of Medicine, Chung Shan Medical University and Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd., Taichung 402, Taiwan, ROC. Tel.: +886-4-2473002 More

Citation:
Wu SW, Ho YC, Luo CW, Chen HY, Su CH, Kuan YH. Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study. Int J Med Sci 2021; 18(3):778-784. doi:10.7150/ijms.55361. https://www.medsci.org/v18p0778.htm
Other styles

File import instruction

Abstract

Objectives: Currently, diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) have proven to be risk factors for each other. This study aimed to determine the risk relationship between COPD and five common oral medications for DM among patients with DM.

Methods: This population-based cohort study was conducted from 2008 to 2013. Patient data were retrieved from the Longitudinal Health Insurance Database (LHID) of the National Health Insurance Research Database (NHIRD). After pairing by gender, age, and index date, time-to-event analysis and multiple regression analysis were performed to determine the factors associated with COPD in patients taking oral medication for DM, including age, gender, income, and comorbidities. We identified 1,028 patients who took oral medication for DM and 1,028 controls who did not take oral medication for DM.

Results: We observed that the use of α-glucosidase inhibitors was associated with a higher risk of COPD (hazard ratio [HR]: 1.964, 95% confidence interval [CI]: 1.207-2.380). Furthermore, compared with the control group, α-glucosidase inhibitor users had a higher risk of COPD (HR: 2.295, 95% CI: 1.304-4.038), and no significant difference was observed in other oral medications for DM.

Conclusions: Based on present results, we could suggest that patients with DM who used α-glucosidase inhibitors are probably a higher risk of COPD. We recommend that in the future, treatment with α-glucosidase inhibitors upregulate the occurrence of COPD might through gastrointestinal side effects and malnutrition.

Keywords: diabetes mellitus, chronic obstructive pulmonary disease, α-glucosidase inhibitor, cohort study, cox regression

Citation styles

APA
Wu, S.W., Ho, Y.C., Luo, C.W., Chen, H.Y., Su, C.H., Kuan, Y.H. (2021). Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study. International Journal of Medical Sciences, 18(3), 778-784. https://doi.org/10.7150/ijms.55361.

ACS
Wu, S.W.; Ho, Y.C.; Luo, C.W.; Chen, H.Y.; Su, C.H.; Kuan, Y.H. Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study. Int. J. Med. Sci. 2021, 18 (3), 778-784. DOI: 10.7150/ijms.55361.

NLM
Wu SW, Ho YC, Luo CW, Chen HY, Su CH, Kuan YH. Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study. Int J Med Sci 2021; 18(3):778-784. doi:10.7150/ijms.55361. https://www.medsci.org/v18p0778.htm

CSE
Wu SW, Ho YC, Luo CW, Chen HY, Su CH, Kuan YH. 2021. Oral treatment for diabetes using α-glucosidase inhibitors was a risk factor for chronic obstructive pulmonary disease: a cohort study. Int J Med Sci. 18(3):778-784.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use